PSI CRO, a full-service contract research organization, announced the launch of a new global study in Polycythemia vera in collaboration with AOP Orphan. PSI is setting up this 100-patient open-label, multicenter study at 45 sites across 13 countries globally.

 

The new project is a result of a successful collaboration on an earlier Phase 3 study of 250+ patients in Polycythemia vera that PSI is managing for AOP Orphan globally. The study is enrolling right on time.

 

Polycythemia vera (PV) is a Rare Disease of the blood-building cells in the bone marrow primarily resulting in a chronic increase of red blood cells (erythrocytes), thereby having an adverse impact on blood rheology. Circulatory disorders such as thrombosis and embolism, as well as malignant transformation to myelofibrosis or leukemia, are possible outcomes of the disease. With proper treatment, the majority of PV patients have a near-normal life expectancy.

 

Date: July 22, 2014

Source: PSI